Myopia

Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President

Retrieved on: 
Thursday, December 8, 2022

“Since joining the company earlier this year, Bren has made significant contributions preparing our manufacturing facility in Redwood City to commence operations, and I believe he is the ideal candidate to serve as the company’s Chief Operating Officer going forward,” stated Michael Rowe, Chief Executive Officer of Eyenovia.

Key Points: 
  • “Since joining the company earlier this year, Bren has made significant contributions preparing our manufacturing facility in Redwood City to commence operations, and I believe he is the ideal candidate to serve as the company’s Chief Operating Officer going forward,” stated Michael Rowe, Chief Executive Officer of Eyenovia.
  • Eyenovia also announced today that independent director Julia Haller, MD is stepping down from the company’s Board of Directors.
  • Developed as a micro-formulation for use without anesthetic, Eyenovia believes Mydcombi will help improve the efficacy, tolerability, and efficiency of pharmacologic mydriasis.
  • Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics.

Purchasing safe toys for children this holiday season can reduce risk of eye trauma: Canadian Ophthalmological Society

Retrieved on: 
Wednesday, December 7, 2022

TORONTO, Dec. 7, 2022 /CNW/ - With the holidays fast approaching, the Canadian Ophthalmological Society wants to stress the importance of purchasing eye-safe toys when shopping this holiday season.

Key Points: 
  • TORONTO, Dec. 7, 2022 /CNW/ - With the holidays fast approaching, the Canadian Ophthalmological Society wants to stress the importance of purchasing eye-safe toys when shopping this holiday season.
  • "That's why eye care professionals recommend avoiding toys that pose a high risk of eye injuries such as lasers, sharp toys, aerosols like silly string, and flying or projectile toys especially if safety glasses are not worn."
  • A survey by the Canadian Ophthalmological Society, in partnership with the Canadian Association of Optometrists, revealed that when it comes to purchasing gifts, only 16 per cent of Canadians report shopping for toys with eye safety in mind.
  • The Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care in Canada.

Insights on the Prescription Lens Global Market to 2030 - Growing Number of Awareness Programs is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022

Therefore, various organizations are focusing on increasing awareness regarding the conditions related to refractive errors and their corrective options.

Key Points: 
  • Therefore, various organizations are focusing on increasing awareness regarding the conditions related to refractive errors and their corrective options.
  • Initiatives taken to enhance vision care, identify cases at an early stage, and provide efficient lenses for treating different vision problems are expected to boost the market growth.
  • Therefore, to provide better treatment for these refractive errors, market players are coming up with different types of prescription lenses with advanced coating options.
  • UV coating prescription lenses are witnessing growth mainly due to their growing demand to avoid penetration of harmful UV radiations.

Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund

Retrieved on: 
Tuesday, November 29, 2022

Per the terms of the agreement, Eyenovia received $10 million of gross proceeds at closing (approximately $9.5 million net).

Key Points: 
  • Per the terms of the agreement, Eyenovia received $10 million of gross proceeds at closing (approximately $9.5 million net).
  • The Avenue facility replaces the companys Silicon Valley Bank facility, which was recently paid off.
  • The Avenue Venture Debt Fund seeks to provide creative financing solutions to high-growth, venture capital-backed technology and life science companies.
  • The Avenue Venture Debt fund is part of the larger group of funds of Avenue Capital Group.

Eyenovia to Present at Upcoming BTIG Ophthalmology Day

Retrieved on: 
Wednesday, November 23, 2022

Investors interested in meeting with Eyenovia at either conference should contact their BTIG representative.

Key Points: 
  • Investors interested in meeting with Eyenovia at either conference should contact their BTIG representative.
  • Eyenovia, Inc. (Nasdaq: EYEN) is a pre-commercial ophthalmic technology company developing a pipeline of microdose array print (MAP) therapeutics.
  • Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression.
  • The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Dopavision Appoints Dr. Dirk Sauer as Chair of the Company's Advisory Board

Retrieved on: 
Wednesday, November 16, 2022

Berlin, Germany, November 16, 2022 --- Dopavision, a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company's Advisory Board. Dirk Sauer brings an exceptional track record in the development of ophthalmic therapeutics and an extensive industry network to advance MyopiaX®, Dopavision's leading-edge digital therapeutic for childhood myopia control. MyopiaX® is currently in clinical trials in Germany, Portugal, Spain, and Ireland.

Key Points: 
  • Berlin, Germany, November 16, 2022 --- Dopavision , a clinical-stage company pioneering the development of digital therapeutics, today announced the appointment of Dr. Dirk Sauer as Chairman of the Company's Advisory Board.
  • Dirk Sauer is an expert in eye therapeutics development with long-standing global experience in ophthalmology and neuroscience.
  • He will be a great addition to our Advisory Board and will provide leadership for the entire R&D team."
  • "I am really excited to chair Dopavision's Advisory Board," said Dr. Dirk Sauer.

Noveome Biotherapeutics, Inc. Announces New Appointments to Board of Directors

Retrieved on: 
Wednesday, November 16, 2022

and Houman D. Hemmati, M.D., Ph.D. to the companys Board of Directors.

Key Points: 
  • and Houman D. Hemmati, M.D., Ph.D. to the companys Board of Directors.
  • Eric Keller is a proven business and legal executive with nearly 30 years of experience in life sciences-based companies.
  • We are delighted to welcome Eric and Houman to our Board of Directors.
  • Noveome has completed a Phase 2 open-label clinical trial that demonstrated the benefit ST266 had in healing persistent corneal epithelial defects (PEDs).

Luminopia, Inc. Announces Oversubscribed Seed Extension Financing Round

Retrieved on: 
Friday, November 11, 2022

Luminopia, Inc., a prescription digital therapeutics company pioneering a new class of treatments for neuro-visual disorders, today announced an oversubscribed $5.7M seed extension financing round.

Key Points: 
  • Luminopia, Inc., a prescription digital therapeutics company pioneering a new class of treatments for neuro-visual disorders, today announced an oversubscribed $5.7M seed extension financing round.
  • ShangBay Capital led the round, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strategy, as well as support from existing investors.
  • With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopias Board of Directors.
  • Upon launch, the therapeutic will be prescribed by eye care professionals and distributed through an online retail pharmacy.

Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the third quarter ended September 30, 2022.

Key Points: 
  • Ended the third quarter of 2022 with approximately $25.3 million in total cash and cash equivalents, including $7.9 million of restricted cash.
  • For the third quarter of 2022, general and administrative expenses were approximately $3.4 million, compared to $2.4 million for the third quarter of 2021, an increase of approximately 41.3%.
  • Total operating expenses for the third quarter of 2022 were approximately $7.2 million compared to $5.9 million for the third quarter of 2021.
  • These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management.

Global Autonomous Car Market Report 2022: Demand from Aging Population for Ease of Transport Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022

An autonomous car or a self-driving car or driverless car is a vehicle capable of sensing the environment and moving safely with little to no human intervention.

Key Points: 
  • An autonomous car or a self-driving car or driverless car is a vehicle capable of sensing the environment and moving safely with little to no human intervention.
  • An autonomous car can go anywhere, similar to a conventional car, and do everything that an experienced human driver does.
  • Moreover, in countries such as the U.S., geriatric population is expected to boost the demand for autonomous cars.
  • Thus, these factors are expected to propel growth of the global autonomous market over the forecast period.